ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,112Medicare Part D Prescriptions Filled, Including Refills

Rank: 215 out of 890

$699K Total Retail Price of All Prescriptions

Rank: 144 out of 890

478 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
39% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

5% of this provider’s 7,896 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
METFORMIN HCL 359 298 1 6
LEVOTHYROXINE SODIUM 349 265 2 2
AMLODIPINE BESYLATE 309 268 3 1
LISINOPRIL 276 228 4 4
SIMVASTATIN 257 227 5 5
FUROSEMIDE 255 179 6 7
WELCHOL 242 184 7 226
HYDROCHLOROTHIAZIDE 224 168 8 9
MELOXICAM 209 158 9 18
OMEPRAZOLE 199 146 10 8
GABAPENTIN 196 143 11 12
CLONIDINE HCL 166 137 12 35
PRAVASTATIN SODIUM 144 107 13 10
METOPROLOL TARTRATE 142 108 14 15
LOVAZA 131 120 15 120
GLYBURIDE MICRONIZED 124 93 R 16 203
BYSTOLIC 119 87 17 86
GEMFIBROZIL 118 98 18 103
CLOPIDOGREL 118 111 18 28
ONGLYZA 114 95 20 146
ATENOLOL 111 69 21 23
AMITRIPTYLINE HCL 110 92 R 22 43
CIPROFLOXACIN HCL 107 87 23 58
BENICAR HCT 99 84 24 166
TRAMADOL HCL 95 74 25 16
LISINOPRIL-HYDROCHLOROTHIAZIDE 93 74 26 21
ZOLPIDEM TARTRATE 83 48 27 19
PAROXETINE HCL 83 69 27 68
BENICAR 83 63 27 180
WARFARIN SODIUM 82 77 30 24
JANUVIA 82 69 30 59
PLAVIX 82 78 30 42
NEXIUM 82 59 30 14
SERTRALINE HCL 79 71 34 26
ATORVASTATIN CALCIUM 78 54 35 13
TRAZODONE HCL 76 48 36 40
CARVEDILOL 76 59 36 22
LYRICA 75 53 38 71
METOPROLOL SUCCINATE 74 69 39 17
CYMBALTA 70 35 40 45
ANTARA 67 48 41 399
ISOSORBIDE MONONITRATE ER 63 53 42 60
CITALOPRAM HBR 62 48 43 20
ALENDRONATE SODIUM 61 50 44 38
ENALAPRIL MALEATE 61 36 44 56
ORPHENADRINE CITRATE 59 52 R 46 372
POTASSIUM CHLORIDE 58 51 47 11
FENOFIBRATE 58 58 47 74
ALLOPURINOL 57 39 49 31
TRIBENZOR 56 48 50 285
FLUTICASONE PROPIONATE 53 41 51 39
TRICOR 53 49 51 98
COLCRYS 53 47 51 150
CRESTOR 50 43 54 25
AZITHROMYCIN 50 37 54 37
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 5, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.